Navigating the First 5 Years and Beyond: Early-Career Strategies and Industry Collaboration

At Winter Clinical Miami, early-career guidance and physician–industry collaboration took center stage. In the first half of the Mentoring for Leadership Session, G. Michael Lewitt, MD, and Gary Goldenberg, MD, focused on practical strategies for new dermatologists navigating contracts, clinical workflows, professional growth, and external partnerships.

Top Ten Pearls and Pitfalls from the First Five Years in Practice

Lewitt opened with pragmatic advice drawn from his first 5 years in practice, emphasizing that early career physicians must think beyond clinical acumen to contract literacy and practice management.¹ His first and most emphatic pearl: get everything in writing. Verbal assurances regarding staffing, patient volume, or resources are meaningless unless explicitly detailed in the employment contract—not merely the offer letter. He stressed the importance of engaging a health care attorney familiar not only with dermatology but also with the specific state’s regulatory environment, noting how differences in malpractice law and employment statutes can materially affect agreements.

Restricted covenants and non-compete clauses warrant particular scrutiny. Physicians should understand geographic scope, duration, and conditions under which covenants may be waived, especially if termination occurs without cause. Lewitt recommended negotiating reasonable radii tied to the primary practice location and considering a “honeymoon period” that allows either party to exit early in the relationship without long-term restriction. While non-competes protect practice investment and return on training, he acknowledged their potential to limit patient access and professional mobility if overly broad.

On the clinical side, Lewitt underscored the value of relationship-building. Early in practice, personally calling patients with biopsy-proven malignancies fosters trust and establishes a reputation for accessibility. Similarly, sending concise communication letters to referring providers reinforces referral pipelines and strengthens professional networks. He also advised maintaining a consistent, systematic approach to total body skin examinations to minimize omissions and distractions.

Among the most common pitfalls, Lewitt highlighted poor scheduling structure. Non-templated clinic schedules can lead to burnout, inefficiency, and mismatched visit types. While he does not universally advocate separate “established” slots, he supports templating once patient volume increases, particularly for high-demand services such as cosmetic consultations or complex inflammatory disease management.

Compensation models represent another area ripe for misunderstanding. Headline salary figures may obscure productivity thresholds, variable compensation formulas, or sign-on bonuses recouped from future earnings. Physicians should clarify whether compensation is fixed or productivity-based, examine thresholds carefully, and consider negotiating extended guarantee periods when transitioning from training to practice.

He also cautioned against stagnation. Dermatology evolves rapidly, and physicians risk reputational harm if they fail to adopt emerging therapeutics. Continuing education, procedural upskilling, and therapeutic diversification remain essential to maintaining relevance and delivering comprehensive care. Finally, Lewitt encouraged selective openness to opportunity. While setting boundaries is important, saying “yes” to lectures, committees, and collaborations can open unforeseen professional doors.

Working With Industry: The Good, The Bad, and the Ugly

Transitioning to physician–industry relationships, Goldenberg offered a balanced perspective shaped by experience both as a consultant and as a former pharmaceutical executive.² Among the benefits, he cited opportunities to shape innovative therapies, influence trial design, and ensure real-world clinical relevance. Industry engagement offers intellectual stimulation beyond routine clinic, exposure to market strategy and manuscript development, and collaboration across specialties, particularly for systemic agents spanning dermatology, rheumatology, and gastroenterology. Financial diversification also provides income stability amid fluctuating reimbursement landscapes.

However, these benefits are accompanied by substantial risks. Ethical conflicts of interest represent the most serious concern. Physicians must never feel pressured to minimize adverse events or preferentially prescribe based on financial relationships. Transparency under federal reporting laws means patients can access information about industry payments, making trust preservation paramount.

Time commitment poses another hazard. Travel, lectures, and advisory roles can erode personal and clinical bandwidth, contributing to burnout. Physicians must assess fair market value relative to lost clinic revenue and family time. Reputational risk is equally significant. Companies may leverage physician likeness or prior content beyond contractual terms, underscoring the need for clear agreements governing image use and intellectual property. Moreover, association with companies later implicated in data irregularities can damage professional standing.

Ultimately, Goldenberg emphasized that collaboration with industry can be rewarding when grounded in ethical clarity, regulatory awareness, and unwavering commitment to patient-centered prescribing.

References

1. Lewitt M. My Top Ten Pearls and Pitfalls from my First Five Years in Practice. Presented at: 2026 Winter Clinical Miami Dermatology Conference; February 27-March 1, 2026; Aventura, FL.

2. Goldenberg, G. Working With Industry: The Good, The Bad, and the Ugly. Presented at: 2026 Winter Clinical Miami Dermatology Conference; February 27-March 1, 2026; Aventura, FL.